MedTrace Logo

Omentectomy for Metabolic Syndrome in Gastric Cancer Patients

NCT02641925 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-06-01

No results posted yet for this study

Summary

Many features of the metabolic syndrome are associated with insulin resistance. And, metabolic syndrome and insulin resistance are related to visceral obesity. Therefore, the investigators hypothesized that visceral fat removal (omentectomy) can make favorable results for the insulin resistance and metabolic syndrome. As the omentectomy is optional procedure during a surgery for early gastric cancer, the investigators will divide patients randomly into two groups, total omentectomy group and omentum preserving group.

Conditions

Interventions

PROCEDURE

Omentum preserving

The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.

PROCEDURE

Total omentectomy

Whole omentum will be removed during gastrectomy with lymph node dissection.

Sponsors & Collaborators

  • Chonnam National University Hospital

    collaborator OTHER

  • Dong-A University Hospital

    collaborator OTHER

  • Keimyung University Dongsan Medical Center

    lead OTHER

Principal Investigators

  • Seung Wan Ryu, M.D., Ph.D. · Korean South West East Gastric Surgery Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2019-08-31
Completion
2020-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02641925 on ClinicalTrials.gov